Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2018 · 10-K
Revenue$28.84M$28.84M+186.9% vs Q4 2017 Net Income-$49.56M-$49.56MN/M vs Q4 2017 EPS Diluted-$0.63-$0.63N/M vs Q4 2017 Gross Profit$17,272,000+98.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$33,487,000N/M Free Cash Flowderived-$36,962,000N/M Margins · derivedGross margin59.9%−26.8 pt vs Q4 2017
Operating margin-177.9%+437.7 pt vs Q4 2017
Net margin-171.8%+449.8 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 22, 2019 · 53 d after period end